Streetbeat News

Revenues

CGEM

Cullinan Therapeutics reported having $664.9 million in cash, cash equivalents, investments, and interest receivable as of June 30, 2024. The company expects these resources to sustain operations until 2028 based on its current operating plan.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:00 pm

KOP

Koppers Holdings (NYSE:KOP) reported Q2 2024 adjusted EPS of $1.36, beating the analyst estimate of $1.27 by 7.09%. However, sales were $563.2 million, missing the $589.867 million estimate by 4.52% and down 2.43% from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:59 am

RAPP

Rapport Therapeutics ended the quarter with $336.1 million in cash, cash equivalents, and short-term investments, excluding restricted cash. This funding is expected to support operations through the end of 2026.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:58 am

PCT

PureCycle has reached an agreement to sell $22.5 million in Southern Ohio Port Authority Revenue Bonds, generating $18 million in cash proceeds. The company ended Q2 FY2024 with $10.9 million in unrestricted cash.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:58 am

RNAC

Cartesian Therapeutics has $88.9M in cash and net proceeds from $130M PIPE financing to support the development of Descartes-08 for Myasthenia Gravis. An end-of-phase 2 meeting with the FDA is expected by year-end.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:56 am

VST

Vistra (NYSE:VST) reported Q2 2024 adjusted EPS of $1.43, beating the analyst estimate of $1.38. However, sales of $3.845 billion missed the $3.964 billion estimate. Sales increased by 20.57% year-over-year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:52 am

ENG

ENGlobal reported a Q2 net loss of $1.2 million and revenues of $6.1 million, which is a 37% decrease year-over-year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:47 am

FA

First Advantage (NASDAQ:FA) reported Q2 2024 adjusted EPS of $0.21, meeting analyst expectations. However, the company's sales of $184.546 million slightly missed the $184.606 million estimate, representing a 0.41% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:45 am

NVAX

Novavax (NASDAQ:NVAX) reported Q2 2024 earnings per share (EPS) of $0.99, missing the analyst consensus estimate of $1.64 by 39.63%. The company also reported quarterly sales of $415.484 million, which missed the analyst consensus estimate of $458.575 million by 9.40%. This represents a 2.11% decrease in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:42 am

PRTH

Priority Technology Holdings, Inc. (PRTH) has revised its FY24 revenue forecast from the previous range of $875M - $890M to a new range of $875M - $883M. The estimated revenue is $874.686M.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:41 am